High Sensitivity and Specificity of a Coagulation Assay for the Detection of Heterozygous and Homozygous
Factor V Leiden-Based Resistance to Activated Protein C To the Editor: 70 nmol/L, 35 nmoUL, 14 nmollL, 7 nmol/L, and 0 nmol/L APC, corresponding to loo%, 50%, 20%, lo%, and 0% factor Va inactivaResistance to activated protein C (APC). caused by a mutated tion, respectively. Here we will summarize our current experience Coagulation factor v (factor v Leiden), has been reported as a predis-with this modified functional assay for the detection of factor V posing factor in a large fraction of patients with venous thromboemLeiden, bolism. Diagnosis of APC resistance is currently based upon measursamples from 197 patients with thrombotic disorders (including 1% the ratio of activated Partial thromboplastin times ( A m s ) in the patients receiving heparin or oral anticoagulants) were evaluated for Presence and absence of exogenous APC. However, determination the presence of the factor V Leiden mutation using the polymerase of this APC resistance ratio is not reliable in patients receiving chain reaction followed by digestion of amplification products with anticoagulant therapy. In their recent review of inherited thrombo~~f l and detection of a restriction fragment length polymorphism philia in Blood, De Stefan0 et all cite unpublished observations as described by ~~r t i~~ et d. 3 I~ all test plasmas APC resistance indicating that predilution Of the test plasma with factor V deficient was analyzed using a commercially available kit to determine the based APC resistance assay for detection of mutant factor V. We our factor Va inactivation assay (Fig l) . Median APC resistance have developed a modified APC resistance assay which not only ratios in patients with wildtype factor v (n = 122, e), heterozygous includes factor V deficient plasma as a consistent supply of vitamin factor V Leiden (n z 65, O), and homozygous factor V Leiden (n K-dependent coagulation factors and inhibitors, but also an addi-= 10, m) were 2.62, 1.95, and 1.4, respectively. The corresponding tional dilution step to reduce the influence of anticoagulants such as values for factor Va inactivation were 1 18%. 34%, and 5%. APC heparin or lupus anticoagulants in the patient plasma samples. Details resistance ratios were falsely negative (above the cutoff level of of this factor Va inactivation assay have been reported previously.2 2.0) in 30 heterozygous patients and 1 homozygous individual. The
Briefly, 50 pL of the plasma samples, prediluted 1:20 with barbital resulting low sensitivity (59%) of this assay for detection of factor acetate buffer, are incubated for 7 minutes at 37°C in the presence V Leiden was expected because anticoagulated patients had been of 50 pL factor V deficient plasma (Immuno, Heidelberg, Germany) included. In 17 patients with wildtype factor V, APC resistance and 50 pL m reagent (Platelin LS, Organon Technika, Eppelratios were lower than 2.0 and thus falsely positive (specificity 86%). heim, Germany). After addition of 50 pL of a 0.025 m o m CaC1, In contrast, sensitivity and specificity of the factor Va inactivation solution containing 70 nmol/L APC (Chromogenix, Molndal, Sweassay (cutoff 60%) for detection of factor V Leiden were 98.7% and den), clotting times are determined and expressed as the percentage loo%, respectively. The falsely negative result in the heterozygous of factor Va inactivation employing a standard curve generated by individual with normal factor Va inactivation was caused by Factor using normal pool plasma and 0. inactivation levels were below 15% in the 10 homozygous patients, but in none of the heterozygotes. In conclusion, the results show a high sensitivity and specificity (overall accuracy 99.5%) of the factor Va inactivation assay for detection of factor V Leiden in unselected patients with thrombotic disorders, including patients receiving anticoagulant therapy. Furthermore, the factor Va inactivation assay may allow a reliable differentiation between patients with hetero-and homozygous factor V Leiden. The absence of any patients without factor V Leiden but with abnormal factor Va inactivation, strongly supports the notion that the factor V Leiden mutation is responsible for the vast majority of factor V-associated cases of an abnormal anticoagulant response to APC. 
